Heather J. Landau, MD
Heather J. Landau is a board-certified oncologist and hematologist, and works as part of a multidisciplinary team caring for patients with hematologic disorders. She received her medical degree from Upstate Medical University followed by residency in internal medicine from University of Colorado Health Sciences Center and fellowship in hematology/oncology from Memorial Sloan Kettering Cancer Center.
Dr. Landau has a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis. Her research focuses on new treatment approaches for plasma cell disorders. Along with her colleagues she is testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases.
She is co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. She is also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, she has had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach.
Representative Publications:
Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody
